Taihua has recommenced natural pharmaceutical ingredients production at its plant in China.
Production was suspended while the Chinese authorities reviewed the licences awarded to all Chinese natural pharmaceutical ingredients suppliers. The local of China’s State Food and Drug Administration has given its approval.
Taihua share rose 0.75p to 11.5p.
© 2026 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds